a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease

Inclusion Criteria

• •1. Signed written informed consent;
• •2. Diagnose as relapsed /refractory multiple myeloma or other plasma cell disease, and meet one of the following conditions:
• •1. Failed to standard chemotherapy regimens;
• •2. Relapse after complete remission, high-risk and / or refractory patients ;
• •3. Relapse after hematopoietic stem cell transplantation;
• •3. Evidence for cell membrane BCMA expression
• •4. All genders, ages: 18 to 75 years#
• •5. The expect time of survive is above 3 months;
• •6. KPS\>60
• •7. No serious mental disorders ;
• •8. Left ventricular ejection fraction ≥50%
• •9. Sufficient hepatic function defined by ALT/AST≤3 x ULN and bilirubin≤2 x ULN;
• •10. Sufficient renal function defined by creatinine clearance≤2 x ULN;
• •11. Sufficient pulmonary function defined by indoor oxygen saturation≥92%; 12. With single or venous blood collection standards, and no other cell collection contraindications;
• •13\. Ability and willingness to adhere to the study visit schedule and all protocol requirements.